A novel and safe approach for treating cognitive disorders
November 28, 2023Umecrine Cognition presents preclinical results showing significant decreases in PBC-like symptomology and neuroinflammationStockholm, November 28, 2023 – Umecrine Cognition AB today announced positive preclinical results that indicate normalizing effects of the clinical...
November 17, 2023Umecrine Cognition raises further funding for the clinical development of golexanoloneSTOCKHOLM – November 17, 2023. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 30,4 million, to...
July 5, 2023Umecrine Cognition presents data at World Parkinson Congress showing positive effects of golexanolone in a preclinical model of Parkinson’s diseaseStockholm, July 5, 2023 – Umecrine Cognition AB today announced that results from a study on a preclinical model of Parkinson’s disease are being...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.